Supernus, Inc.
Indivior develops and commercializes medicines for opioid use disorder (OUD), primarily for patients and healthcare providers in the U.S. Its core products are SUBLOCADE, a monthly extended-release buprenorphine injection, and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also distributes SUBUTEX buprenorphine tablets, mainly in Australia, France and Germany, and SUBOXONE tablets on a transition basis in a limited number of countries. Indivior’s products are available primarily in the U.S., with additional markets including Canada, Australia, France and Germany. Indivior makes money by selling its medicines. Its U.S. sales are limited to SUBLOCADE and SUBOXONE Film. The company also has two new drug candidates for OUD in its development pipeline. Indivior is headquartered in Richmond, Virginia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $INDV in the last 30 days.
See all $INDV insider activity →Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.
Argus raised its target price for Supernus Inc. (SUPN) to $30.00, maintaining a 'Hold' rating. The company has medium ratings for industry, management, safety, financial strength, and growth, with a high value subrating.
Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning INDV (Supernus, Inc.). Coverage has skewed bullish: 5 bullish, 0 neutral, and 0 bearish.
Recent INDV coverage spans financial news, mergers & acquisitions and corporate actions.
Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.
Argus raised its target price for Supernus Inc. (SUPN) to $30.00, maintaining a 'Hold' rating. The company has medium ratings for industry, management, safety, financial strength, and growth, with a high value subrating.
Indivior benefits from the combined revenue growth narrative.
Stock futures rose midweek after Democrats won midterm elections. Nasdaq, S&P 500, and Russell 2000 gained, while Dow Jones fell. Analysts upgraded Duolingo (DUOL), Fiserv (FISV), and Fortinet (FTNT), among others, and downgraded Adobe (ADBE), Apple (AAPL), and Exxon Mobil (XOM).
Cantor Fitzgerald kept its Overweight rating on Supernus and increased its price target to $87 from $67, suggesting a 107.5% upside from the Oct 30 close of $41.92, according to the firm.
AlphAI scores every news story that mentions INDV with an AI model for sentiment and relevance, and aggregates insider trades from Supernus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bank of America analysts see significant upside in Iambic Therapeutics (95%) and Supernus Pharmaceuticals (60%). Iambic's AI-driven cancer treatment IAM1363 showed promising early results, while Supernus's merger with Indivior is expected to drive revenue growth. Both stocks are rated Buy with specific price targets.
Argus raised its target price for Supernus Inc. (SUPN) to $30.00, maintaining a 'Hold' rating. The company has medium ratings for industry, management, safety, financial strength, and growth, with a high value subrating.
Bank of America initiated coverage of Supernus Pharmaceuticals (SUPN) with a 'buy' rating and $47 price target, citing its merger with Indivior. The combined entity is expected to have a broader portfolio and stronger earnings potential. Bank of America forecasts 6% annual revenue and EPS growth over five years, with legacy Supernus products driving two-thirds of revenue growth.
Stock futures rose midweek after Democrats won midterm elections. Nasdaq, S&P 500, and Russell 2000 gained, while Dow Jones fell. Analysts upgraded Duolingo (DUOL), Fiserv (FISV), and Fortinet (FTNT), among others, and downgraded Adobe (ADBE), Apple (AAPL), and Exxon Mobil (XOM).
Cantor Fitzgerald kept its Overweight rating on Supernus and increased its price target to $87 from $67, suggesting a 107.5% upside from the Oct 30 close of $41.92, according to the firm.
Piper Sandler resumed coverage of Supernus Pharmaceuticals (SUPN) with an Overweight rating and $47 price target. The stock trades at $28.15, with analysts' price targets ranging from $55 to $67. The firm cited strong strategic logic post-merger, with expected 2027 EBITDA over $1B and net debt around $800M. Key products include Sublocade, Qelbree, Zurzuvae, and Onapgo, which should drive 80% of 2027 revenue.
Supernus Pharmaceuticals increased the conversion rate of its 0.625% Convertible Senior Notes due 2031 to 30.9355 shares per $1,000 principal amount, reflecting a conversion price of $32.33 per share. The change followed a special dividend, but no bondholders converted their notes into common stock.
Supernus, Inc. (INDV) filed an SEC Form 8-K — Other Events. Item 8.01 Other. Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “ Indenture ”), governing the Company's 0.
Supernus Pharmaceuticals (SUPN) secured a $650 million senior secured term loan from Citibank and other lenders on November 2, 2026. The funds will support a merger, refinance existing debt, and cover transaction costs. Interest rates are based on Term SOFR or the Base Rate plus applicable margins, varying by leverage.
Indivior Pharmaceuticals appointed Jack A. Khattar as CEO. Four executives departed with separation agreements totaling $1.67M to $2.2M each. Khattar's employment agreement includes a $1.115M base salary and a 100% target bonus. The changes follow a merger agreement, with resignations not due to disagreements.
